New and Emerging Biologics for the Treatment of Psoriasis

The discussion on new and emerging biologics for psoriasis highlights the remarkable advancements in treatment options over the last 25 years. Emphasizing the broadening definition of biologics, the talk defines them as therapeutic agents derived from living organisms, such as monoclonal antibodies and peptides. The speaker introduces bemakizumab, a novel therapy targeting IL-17A and IL-17F, celebrating its high efficacy rates and rapid response times in adult patients with plaque psoriasis. The advantages of biologics are rooted in the straightforward immunological pathways they target, with psoriasis offering a clear pathway for drug development. Notably, the efficacy and safety of bemakizumab demonstrate excellent maintenance of treatment response over extended periods, and it has been effective in treating psoriatic arthritis as well. Additionally, the discussion touches on future biologics like oral formulations and nanobodies, alongside the emerging trend of biosimilars, which present cost-saving opportunities yet warrant careful management to avoid immunogenicity issues. The future holds promise for innovative treatments, ensuring that biologic therapy continues to evolve and improve outcomes for patients with psoriasis.